Comparative Pharmacology
Head-to-head clinical analysis: CLENZ LYTE versus LACTULOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLENZ LYTE versus LACTULOSE.
CLENZ-LYTE vs LACTULOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Colon lavage solution that osmotically induces diarrhea to cleanse the colon.
Lactulose is a non-absorbable disaccharide that is metabolized by colonic bacteria to short-chain fatty acids, primarily lactic acid and acetic acid, resulting in an osmotic effect that increases stool water content and softens stools. In hepatic encephalopathy, lactulose acidifies the colonic lumen, converting NH3 to NH4+, which is poorly absorbed, and reduces systemic ammonia levels.
Oral: 4 L (or 240 mL every 10 minutes) administered the evening before colonoscopy; alternatively, 2 L (or 240 mL every 10 minutes) plus 2 L of clear liquids given in split doses (first 1-2 L evening before, remaining in morning of procedure).
Constipation: 15-30 mL (10-20 g) orally once daily, increased to 45-60 mL (30-40 g) daily if needed. Hepatic encephalopathy: 30-45 mL (20-30 g) orally 3-4 times daily; titrate to produce 2-3 soft stools daily.
None Documented
None Documented
Clinical Note
moderateL-Glutamine + Lactulose
"The therapeutic efficacy of Lactulose can be decreased when used in combination with L-Glutamine."
Not applicable; systemic absorption is negligible (plasma levels below detection limits). Clinical effect is localized to gastrointestinal tract.
1-2 hours (terminal elimination half-life for lactulose). However, its clinical effect is not dependent on systemic half-life; the drug acts locally in the colon.
Primarily fecal (approximately 95%) as unabsorbed polyethylene glycol; negligible renal excretion (<5%) as intact polymer.
Primarily fecal (unaltered, >90%). Minimal renal excretion (<5% as metabolites). Very small amount (approximately 3%) excreted in urine as unchanged drug.
Category C
Category C
Laxative
Laxative